KREJČÍ, Jan, Petr HUDE, Eva OZABALOVA, Dalibor MLEJNEK, Víta ŽAMPACHOVÁ, Iva SVOBODOVÁ, Radka STEPANOVA and Lenka ŠPINAROVÁ. Improvement of left ventricular systolic function in inflammatory cardiomyopathy: What plays a role? Biomedical Papers of the Faculty of Medicine of Palacký University. Olomouc: Palacký University, 2016, vol. 160, No 4, p. 524-532. ISSN 1213-8118. Available from: https://dx.doi.org/10.5507/bp.2016.033.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Improvement of left ventricular systolic function in inflammatory cardiomyopathy: What plays a role?
Authors KREJČÍ, Jan (203 Czech Republic, guarantor, belonging to the institution), Petr HUDE (203 Czech Republic), Eva OZABALOVA (203 Czech Republic), Dalibor MLEJNEK (203 Czech Republic, belonging to the institution), Víta ŽAMPACHOVÁ (203 Czech Republic, belonging to the institution), Iva SVOBODOVÁ (203 Czech Republic, belonging to the institution), Radka STEPANOVA (203 Czech Republic) and Lenka ŠPINAROVÁ (203 Czech Republic, belonging to the institution).
Edition Biomedical Papers of the Faculty of Medicine of Palacký University, Olomouc, Palacký University, 2016, 1213-8118.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30201 Cardiac and Cardiovascular systems
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 0.894
RIV identification code RIV/00216224:14110/16:00090789
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.5507/bp.2016.033
UT WoS 000392810500011
Keywords in English inflammatory cardiomyopathy; endomyocardial biopsy; echocardiography; NTproBNP; right heart catheterization
Tags EL OK
Tags International impact, Reviewed
Changed by Changed by: Ing. Mgr. Věra Pospíšilíková, učo 9005. Changed: 1/3/2017 09:11.
Abstract
Aims. To compare the differences between patients with inflammatory cardiomyopathy (ICM) with and without improvement in left ventricular (LV) systolic function and to identify the relevant predictors of LV improvement. Patients and Methods. The study included 63 patients with biopsy-proven ICM and heart failure symptoms of at least NYHA II, symptom duration <= 6 months, LV ejection fraction (LVEF) <= 40% assessed by echocardiography and presence of >14 mononuclear leukocytes (LCA+ cells)/mm2 in biopsy samples. Patients were evaluated at baseline and after 6 months. Results. In the group with LVEF improvement of >= 10% (I+ group, n = 41), LVEF increased from 24 ± 7% to 47 ± 8% (P < 0.001). In 22 patients (group I-), there was no or minimal LVEF increase (< 10%). In the I+ group, there were more LCA+ cells/mm2 at baseline (25.1 ± 16.5 vs. 18.5 ± 4.4 cells/mm2; P = 0.032) and a more significant decrease in LCA+ cells in the follow-up (reduction of 13.6 ± 14.3 cells/mm2 vs. 5.0 ± 7.7 cells/mm2 in the I- group; P = 0.009). The univariate logistic regression showed a possible association of number of LCA+ cells, LV end-diastolic diameter and N-terminal fragment of pro-brain natriuretic peptide (NTproBNP) value with LVEF improvement. In the multivariate analysis, only NTproBNP at diagnosis was confirmed as an independent predictor of LVEF improvement (OR=1.2; 1.003 to 1.394; P = 0.046). Conclusion. The LV systolic function improvement was observed in 65% of the patients. In these patients, the number of inflammatory cells at baseline was higher and decreased more but the higher baseline NTproBNP value was the only independent predictor of LVEF improvement.
Links
MUNI/A/1270/2015, interní kód MUName: Význam bioptické diagnostiky u nově vzniklé dilatační kardiomyopatie
Investor: Masaryk University, Category A
PrintDisplayed: 7/10/2024 04:18